CPAs have been implemented for the management of a wide variety of chronic disease conditions, including diabetes mellitus, asthma and high blood pressure. There is evidence that CP A has shown positive health outcomes for the patients involved. Pharmacists working with CPA providers have been shown to contribute to providing better quality of care in the oncology environment, including the treatment of anti-vomiting treatments. In these parameters, CPAs have improved the achievement of target laboratory target values, such as hemoglobin A1c for diabetic patients, improved lung function of asthmatics, and improved blood pressure control in people with high blood pressure.  Arkansan CPAs apply to individual pharmacists, practitioners admitted as “authorized practitioners to prescribe drugs” and patients. The specific disease stipulates that pharmacists administer, with indicated medications that the pharmacist can use are necessary. Pharmacists are required to document their interventions for discussion with the collaborative practitioner and must keep these records for at least 2 years after the date of registration.  In 2010, the American Medical Association (AMA) published a series of reports entitled “AMA Scope of Practice Data Series.”  One report focused on the pharmacy profession, which criticized the formation of CPAs as an attempt by pharmacists to intervene with the physician. In response to the report, a collaboration of seven national pharmacists` associations prepared a response to the WADA Pharmacists Report.  The response called on WADA to correct its report and publish the revised report with Errata.
 In 2011, the WADA Chamber of Deputies adopted a more flexible tone of the APhA in response to contributions from aPhA and other professional pharmacy organizations and finally adopted the following resolution, which focused attention on the rejection of independent (rather than collaborative or dependent) practical agreements: in a commentary for the American College of Clinical Pharmacy (ACCP) of 2011 , Health Policy Advisor and Physician Terry McInnis stressed the need for collaboration between pharmacists and physicians to improve patient outcomes and costs. In the last paragraph, it appeals to pharmacists interested in monitoring CPAs: The Arizona CPAs apply to individual pharmacists and practitioners legally designated as “providers.” Providers include established doctors or nurses. The CPA must indicate the conditions of the disease, the medications, the conditions of notification of the supplier and the laboratory tests that the pharmacist can order. Pharmacists may monitor or modify a patient`s drug treatment in accordance with CPA, provided that the provider and pharmacist have a reciprocal patient-practitioner relationship with the patient.  Starting in 2010, Medicare Part B will not be reimbursed to pharmacists.  The Pharmacy and Medically Underserved Areas Enhancement Act (H.R.